Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-03-19
2011-11-29
Berch, Mark (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S263200, C514S263370, C514S263380, C544S118000, C544S276000
Reexamination Certificate
active
08067413
ABSTRACT:
The present invention provides compounds of formula (I)wherein R1, Y1, X1, L and R2are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
REFERENCES:
patent: 4179562 (1979-12-01), Ponsford
patent: 4689338 (1987-08-01), Gerster
patent: 4698348 (1987-10-01), Gerster
patent: 4714701 (1987-12-01), Beauchamp
patent: 4912112 (1990-03-01), Seydel et al.
patent: 5736549 (1998-04-01), Beasley et al.
patent: 5994361 (1999-11-01), Penney et al.
patent: 6028076 (2000-02-01), Hirota et al.
patent: 6110923 (2000-08-01), Ely
patent: 6329381 (2001-12-01), Kurimoto et al.
patent: 6376501 (2002-04-01), Isobe et al.
patent: 6448236 (2002-09-01), Monaghan
patent: 6458798 (2002-10-01), Fujita et al.
patent: 6630478 (2003-10-01), Diamond et al.
patent: 6887880 (2005-05-01), Levy et al.
patent: 6951866 (2005-10-01), Fujita et al.
patent: 7157465 (2007-01-01), Isobe et al.
patent: 7642350 (2010-01-01), Pryde
patent: 7691877 (2010-04-01), Jones et al.
patent: 2002/0040032 (2002-04-01), Glasky et al.
patent: 2002/0128264 (2002-09-01), Taylor et al.
patent: 2003/0144283 (2003-07-01), Coleman et al.
patent: 2003/0191086 (2003-10-01), Hanus et al.
patent: 2003/0212092 (2003-11-01), Heppner et al.
patent: 2004/0019048 (2004-01-01), Crooks et al.
patent: 2004/0204438 (2004-10-01), Crooks et al.
patent: 2004/0214192 (2004-10-01), Hashida et al.
patent: 2004/0229897 (2004-11-01), Crooks et al.
patent: 2005/0054590 (2005-03-01), Averett et al.
patent: 2005/0119273 (2005-06-01), Lipford et al.
patent: 2006/0052403 (2006-03-01), Isobe et al.
patent: 2006/0252774 (2006-11-01), Vatner et al.
patent: 2007/0190071 (2007-08-01), Kurimoto et al.
patent: 2007/0225303 (2007-09-01), Ogita et al.
patent: 2007/0249638 (2007-10-01), Giorgio et al.
patent: 2008/0008682 (2008-01-01), Chong et al.
patent: 2008/0269240 (2008-10-01), Hashimoto et al.
patent: 2008/0300244 (2008-12-01), Bonnert et al.
patent: 2009/0047249 (2009-02-01), Graupe et al.
patent: 2009/0082332 (2009-03-01), Abbot et al.
patent: 2009/0099216 (2009-04-01), Millichip et al.
patent: 2009/0105212 (2009-04-01), Isobe et al.
patent: 2009/0118263 (2009-05-01), Hashimoto et al.
patent: 2009/0131458 (2009-05-01), Lazarides et al.
patent: 2009/0143400 (2009-06-01), McInally et al.
patent: 2009/0192153 (2009-07-01), Hashimoto et al.
patent: 2009/0202484 (2009-08-01), Chong et al.
patent: 2009/0209524 (2009-08-01), Bennett et al.
patent: 2009/0281075 (2009-11-01), Roughton et al.
patent: 2009/0324551 (2009-12-01), Carson et al.
patent: 2009/0325877 (2009-12-01), Grunt et al.
patent: 2010/0075995 (2010-03-01), Biggadike et al.
patent: 2010/0087443 (2010-04-01), Bonnert et al.
patent: 2010/0093998 (2010-04-01), Isobe et al.
patent: 2010/0099870 (2010-04-01), Isobe et al.
patent: 2010/0120799 (2010-05-01), Lazarides et al.
patent: 2010/0130491 (2010-05-01), Bonnert et al.
patent: 2010/0240623 (2010-09-01), Cook et al.
patent: 2010/0280001 (2010-11-01), Bonnert et al.
patent: 2010/0298364 (2010-11-01), Bennett et al.
patent: 2011/0028715 (2011-02-01), Isobe et al.
patent: 2011/0054168 (2011-03-01), Kurimoto et al.
patent: 1220148 (1987-04-01), None
patent: 101239980 (2008-08-01), None
patent: 1035123 (2003-08-01), None
patent: 1728793 (2006-12-01), None
patent: 1908480 (2008-04-01), None
patent: 1375162 (1974-11-01), None
patent: 347422/1997 (1997-11-01), None
patent: 367449/1997 (1997-12-01), None
patent: 367451/1997 (1997-12-01), None
patent: 10-501533 (1998-02-01), None
patent: 11-180981 (1999-07-01), None
patent: 11-180982 (1999-07-01), None
patent: 11-193282 (1999-07-01), None
patent: 2000-159767 (2000-06-01), None
patent: 2004-137157 (2004-05-01), None
patent: 2005-089334 (2005-04-01), None
patent: WO 99/05024 (1999-10-01), None
patent: WO 00/12487 (2000-03-01), None
patent: WO 00/76519 (2000-12-01), None
patent: WO 03/011864 (2003-02-01), None
patent: WO 2004/075865 (2004-09-01), None
patent: WO 2004/087049 (2004-10-01), None
patent: WO 2005/092892 (2005-10-01), None
patent: WO 2005/092893 (2005-10-01), None
patent: WO 2006/029115 (2006-03-01), None
patent: WO 2006/091394 (2006-08-01), None
patent: WO 2007/031726 (2007-03-01), None
patent: WO 2007/034173 (2007-03-01), None
patent: WO 2007/034817 (2007-03-01), None
patent: WO 2007/034881 (2007-03-01), None
patent: WO 2007/034882 (2007-03-01), None
patent: WO 2007/034916 (2007-03-01), None
patent: WO 2007/034917 (2007-03-01), None
patent: WO 2007/093901 (2007-08-01), None
patent: WO 2008004948 (2008-01-01), None
patent: WO 2008/114006 (2008-09-01), None
patent: WO 2008/114817 (2008-09-01), None
patent: WO 2008/114819 (2008-09-01), None
patent: WO 2008/135791 (2008-11-01), None
patent: WO 2009067081 (2009-05-01), None
patent: WO 2009/078798 (2009-06-01), None
patent: WO 2009091031 (2009-07-01), None
patent: WO 2009091032 (2009-07-01), None
patent: WO 2010018131 (2010-02-01), None
patent: WO 2010018134 (2010-02-01), None
patent: WO 2010/033074 (2010-03-01), None
Chavarot, “Synthesis of an adenine-pyridinaldoxime-acridine conjugate for recognition of abasic site lesions in DNA,” Tetrahedron, 1997, 53(40), pp. 13749-13756.
Dvorakova, “Synthesis of 2′-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents,” J. Med. Chem., 1996, 39(17), pp. 3263-3268.
Hirota et al., “Discovery of 8-hydroxyadenines as a novel type of interferon inducer,” J. Med. Chem., 2002, 45 (25), pp. 5419-5422.
Holy et al., “Studies on S-adenosyl-L-homocysteine hydrolase. XVI. 9-(Aminoalkyl)-8-hydroxyadenines: preparation mechanism of formation, and use in affinity chromatography of S-adenosyl-L-homocysteine hydrolase,” Collection of Czechoslovak Chemical Communications (1986), 51(2), pp. 459-477.
Isobe et al., “Synthesis and structure-activity relationships of 2-substituted-8-hydroxyadenine derivatives as orally available interferon inducers without emetic side effects,” Bioorganic & Medicinal Chemistry, 2003, 11(17), pp. 3641-3647.
Isobe, Y et al., “Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers,” J. Med. Chem., 2006, 49 (6), pp. 2088-2095.
Itahara, “Control of liquid-crystalline properties by base pairing of adenine and thymine,” ChemPhysChem, 2002, 3(4), pp. 378-379.
Kurimoto et al., “Prodrugs of 9-benzyl-8-hydroxy-2-(2-hydroxyethylthio)adenine: potent interferon inducing agents in monkeys,” Chemical & Pharmaceutical Bulletin, 2004, 52(4), pp. 466-469.
Kurimoto et al., “Synthesis and biological evaluation of 8-oxoadenine derivatives as Toll-like Receptor 7 agonists introducing the antedrug concept,” J. Med. Chem., 2010, 53, pp. 2964-2972.
Kurimoto et al., “Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities,” Bioorganic & Medicinal Chemistry, 2004, 12(5), pp. 1091-1099.
Kurimoto et al., “Synthesis and structure-activity relationships of 2-amino-8-hydroxyadenines as orally active interferon inducing agents,” Bioorganic & Medicinal Chemistry, 2003, 11(24), pp. 5501-5508.
Priority Document of WO 2009005687, (2007).
Spassova et al., “Synthesis ofN-(3-Azido-2-hydroxypropyl),N-(3-Phthalimido-2-hydroxypropyl) andN-(3-Amino-2-hydroxypropyl) Derivatives of Heterocyclic Bases,” Collection of Czechoslovak chemical Communications (1994), 59(5), 1153-1174.
“Asthma” (MDAdvice.com) retrieved on Jun. 24, 2010 from the internet (URL: http://www.mdadvice.com/topics/asthma/info/1.htm).
“Chronic obstructive pulmonary disease”(AllRefer.com Health) retrieved on Jun. 24, 2010 from the internet (URL: http://health.allrefer.com/health/chronic-obstructive-pulmonary-disease-prevention.html).
“Respiratory experts call for global approach to treat chronic diseases” (Feb. 13, 2007) retrieved on Jun. 24, 2010
Bonnert Roger Victor
McInally Thomas
Thom Stephen
AstraZeneca AB
Berch Mark
Dainippon Sumitomo Pharma Co. ,Ltd.
Morgan & Lewis & Bockius, LLP
LandOfFree
9-substituted-8-oxo-adenine compounds as toll-like receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 9-substituted-8-oxo-adenine compounds as toll-like receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 9-substituted-8-oxo-adenine compounds as toll-like receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4303861